Company intelligence / Profile preview
Extrawell Pharmaceutical
Changchun, Jilin, Chinaextrawell.com.hk ↗
- Ownership
- Private
- Employees
- ~159
- Development stage
- Commercial
01
Overview
Extrawell Pharmaceutical develops, manufactures, markets, and distributes a range of pharmaceutical products in China and Hong Kong. Its portfolio includes marketed drugs such as transfer factor oral solution for immune regulation and Wisk for skin injuries. The company is also developing an oral insulin product currently in clinical trials with commercialization expected around Q1 2026. Clinical progress was delayed by COVID-related disruptions but has resumed.
- Therapeutic areas
- DermatologyCardiovascularEndocrinologyInfectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
not explicitly listed; works with business partners to develop new lines of imported pharmaceuticals
Beyond the preview
Go deeper on Extrawell Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Extrawell Pharmaceutical.